Currently approved ASO‐based treatments include eplontersen for hereditary transthyretin amyloidosis with polyneuropathy,28 olezarsen for familial chylomicronemia syndrome,29 eteplirsen for Duchenne muscular dystrophy30 and tofersen for superoxide dismutase 1 (SOD1) related ALS.31 This evidence concerns the gene SOD1 and polyneuropathy.